Discover answers to the most commonly asked questions about BioAR Trial
Simply hit the “Apply Now” button on this website! This will take you to Award Force, which is our third-party platform used for receiving and reviewing applications.
In the online application you’ll complete on Award Force, you’ll be asked to provide responses to several questions, with a character limitation for each answer. Additionally, you’ll be able to submit any additional documents you’d like for us to see, including research papers, business plans, pitch decks, protocols, videos, etc. Once your application has been submitted, the HealthTech Arkansas and SymBiosis teams will review your application, with a goal of selecting 10-15 “finalist” applications to be presented to our participating sites in Arkansas. A selection committee comprised of participants from our trial sites will interview all finalist companies before choosing five companies to be invited to participate in the program each year. Those five companies will receive the benefits listed above.
We’re looking primarily for late pre-clinical companies (those moving into their Phase I clinical trials within 12 months), as well as early clinical companies seeking to initiate a Phase II or Phase III trial within 12 months of entering the program.
Absolutely! We anticipate international companies will target our program to reach U.S. patients, access the U.S. market, and collect data that will be instrumental in achieving U.S. FDA approval.
Applicants developing advanced biotherapeutics in any disease area are welcome to apply, though we have a particular emphasis on oncology, immunology, metabolic and cardiovascular diseases.
Yes, the University of Arkansas for Medical Sciences (“UAMS”) is a committed participant of the program through the Winthrop Rockefeller Cancer Institute and through other areas of clinical research focus. Additionally, the Arkansas Children’s Research Institute is affiliated with UAMS and can host trials with pediatric patients.
No! There’s absolutely no requirement for your company to be in Arkansas for a certain period of time during the program, or for your company to establish operations here. During the course of your trials, your representatives will be onsite as needed, just as if you’re conducting a clinical trial anywhere else in the world.
For companies that are accepted into the program, the program will take $50,000 of in-kind equity in your company, for the services and benefits provided.
Kx Advisors provides advisory services to help leading pharmaceutical, biotechnology, and medical technology companies fully capitalize on product opportunities, navigate the environment with greater certainty, and maximize the lifetime commercial value of their portfolios. Kx Advisors will conduct a virtual seminar for the cohort companies, followed by one-on-one follow-up session for reach company.
Laina Enterprises offers an end-to-end solution for Clinical Research Management Systems, which an invaluable tool to the participating biotherapeutics companies conducting clinical trials. This tool will be available at no cost to BioAR Trial companies.